Skip to main content
Figure 6 | BMC Cancer

Figure 6

From: Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease – a combined tissue microarray, in vitro and in vivo study

Figure 6

Rapamycin inhibits tumor growth in vivo. a. Rapamycin inhibits tumor growth in KMH2 (Hodgkin-lymphoma) xenografts in vivo. Tumor volumes are shown in control and rapamycin-treated mice during an 8-week treatment. Tumor weight at the end of the experiment is also indicated; tumors in rapamune treated mice were significantly smaller (p<0.05). b. Confirmation of the in vivo anti-proliferative and apoptotic effect of rapamycin by IHC detection of pHH3 (proliferation marker) and cleaved/activated caspase3 (apoptosis marker) (*:p<0.05, **:p<0.01).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us